Dietary Intake of Vitamins in Different Options of Treatment in Chronic Kidney Disease: Is There a Deficiency?

Magdalena Jankowska(Gdańsk Medical University), Sylwia Małgorzewicz(Gdańsk Medical University), Alicja Dębska‐Ślizień(Gdańsk Medical University), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Małgorzata Kaczkan(Gdańsk Medical University), N. Szupryczyńska(Gdańsk Medical University), Paulina Borek(Gdańsk Medical University)

Transplantation Proceedings

June 1, 2016

10.1016/j.transproceed.2015.11.039

Cited by 29

Related Papers

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

|The Lancet|2012|3k

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

|The Lancet|2012|1.4k

Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma

|New England Journal of Medicine|2021|869

Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial

|The Lancet Oncology|2020|482

Imatinib Mesylate in Advanced Dermatofibrosarcoma Protuberans: Pooled Analysis of Two Phase II Clinical Trials

|Journal of Clinical Oncology|2010|401